


- A011104 **SUSPENDED**** ALLIANCE- Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer (**Feig**)
- UCI 15-83** Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging in a Multi-Center Setting (**Tromberg**)
- UCI 10-39** Predicting, Pathologic Response w/in the 1st Week of Neoadjuvant ChemoTx Using Functional Parameters Measured Using Diffuse Optical Spectroscopic Imaging (**Tromberg**)
- UCI 11-15** Correlation of Clinical & MRI Finding w/ Prognosis of Breast CA Patients (**Su**)
- UCI 11-21** Analysis of Imaging Features of Breast Diseases and Breast Density Evaluated on Mammogram, Ultrasound & MRI Collected in a Database (**Su**)
- UCI 14-86** Predicting Neoadjuvant Chemotherapy Response by Using a Combined MRI and Scinti-Mammography (MRI-SMM) System (**Su**)
- UCI 14-85** Improving Diagnosis of Breast Cancer by Using a Combined MRI and Positron Emission Mammography (MRI-PEM) System (**Su**)
- UCI 16-23** A Preference-Tolerant RCT of Personalized vs. Annual Screening for Breast Cancer –(WISDOM Study)-Women Informed to Screen Depending On Measures of Risk (**Anton-Culver**)

SCREENING/ DIAGNOSTIC/EPIDEMIOLOGIC/INTERVENTIONAL

BREAST CANCER

CORRELATIVE/ OBSERVATIONAL

- UCI 95-29** Measurement of Breast Optical properties (**Tromberg**)
- UCI 10-24** ATHENA Breast Health Network (**Anton-Culver**)
- UCI 12-10** Development of a Quantitative Tissue Optical Index of Breast Density for Prediction of Hormone Therapy Response (**O’Sullivan**)
- UCI 13-19** Registry Study of Patients Treated with Neoadjuvant Chemotherapy Followed by mastectomy in Stage I, II, III Breast Cancer (**Daroui**)
- UCI 14-25** Plasma Exosome Concentration in Cancer Patients Undergoing Treatment (**Nelson**)
- UCI 14-62** Breast Tumor Oxygenation During Exercise (**Tromberg**)
- UCI 14-81** A Self-discovery tool for Latina Breast cancer Survivors (**Sorkin**)
- UCI 15-64** A Registry Trial of Targeted Intraoperative Radiation Therapy Following Breast-conserving Surgery (**Police**)
- UCI 16-01** (PAINT)-Pathway Analyses for Individualized Network Therapeutics for Cancer (**Nelson**)



Multiple Disease Site

UCI 17-50** A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors (**Ou**)

Stage I-III

UCI 14-67 A Phase II Study of Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel with Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting (**Mehta**)

HER2- High Risk

SWOG S1207 Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer. (**Nangia**)

SWOG S1418 Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy (**Nangia**)

Hormone+ High Risk

NSABP B51 A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (**Daroui**)


Alliance A011502

A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial (**Nangia**)

Advanced

UCI 17-45 COMPLEMENT-1: An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease (**Parajuli**)

Metastatic



Targeted therapy

ECOG-EAY131 (MATCH)-Molecular Analysis for Therapy Choice (**Seery**)

NRG BR002 A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer (**Daroui**)

UCI 16-74 A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician's Choice (TPC) in Patients with Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated with an Anthracycline, a Taxane, and Capecitabine (**Carrillo**)